---
title: "KPV Peptide (α-MSH 11-13): Complete Research Guide — Melanocortin Receptor Selectivity and NF-κB Modulation"
id: "597"
type: "post"
slug: "kpv-peptide-%ce%b1-msh-11-13"
published_at: "2026-08-14T03:34:56+00:00"
modified_at: "2026-08-07T03:36:57+00:00"
url: "https://rplpeptides.com/kpv-peptide-%ce%b1-msh-11-13/"
markdown_url: "https://rplpeptides.com/kpv-peptide-%ce%b1-msh-11-13.md"
excerpt: "KPV Peptide (α-MSH 11–13): Complete Research Guide Melanocortin Receptor Selectivity, NF-κB Modulation, and Structure-Activity Relationships — Updated 2026 This page is a standalone deep-dive companion to the KLOW Peptide Blend Scientific Primer. It covers KPV exclusively. For context on the..."
taxonomy_category:
  - "RPL Peptide"
---

# KPV Peptide (α-MSH 11–13): Complete Research Guide

**Melanocortin Receptor Selectivity, NF-κB Modulation, and Structure-Activity Relationships — Updated 2026**

> **This page is a standalone deep-dive companion to the** [KLOW Peptide Blend Scientific Primer](https://rplpeptides.com/what-is-klow-peptide-blend/)
> . **It covers KPV exclusively. For context on the four-peptide KLOW blend, refer to the pillar document.**

---

## TL;DR — Key Takeaways

- **KPV** (H-Lys-Pro-Val-OH) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), corresponding to α-MSH(11–13). It is the smallest component of the KLOW peptide blend at **342 Da**.
- Unlike the other three KLOW components, KPV’s primary mechanism is **receptor-mediated** — it binds melanocortin receptors (MCRs) rather than targeting the ECM or cytoskeleton directly.
- KPV retains sub-nanomolar affinity for **MC1R** (Ki = 0.81 ± 0.18 nM) but exhibits a ~23-fold reduction at **MC4R** (Ki = 48.2 ± 9.6 nM), producing a functionally significant **MC4R-sparing** selectivity profile.
- It modulates **NF-κB signaling indirectly**: MC1R → cAMP → PKA → IκBα stabilization → reduced p65 nuclear translocation. This effect is abolished by the PKA inhibitor H-89.
- The **evidence base is narrow**: approximately 40 publications exist, concentrated among melanocortin pharmacology groups (Getting/Perretti, UK; Brzoska/Luger, Germany).
- KPV is supplied exclusively as a **research chemical** (CAS 64883-54-9, PubChem CID 123870) for in vitro laboratory investigation. It has not been evaluated by the FDA. Research-grade [KPV peptide from qualified suppliers](https://rplpeptides.com/kpv-peptide-supplier-china/) is typically manufactured via solid-phase peptide synthesis (SPPS) with ≥98% HPLC purity.

---

## Table of Contents

1. [Molecular Identity](#1-molecular-identity)
2. [POMC Processing: The Full Biosynthetic Pathway](#2-pomc-processing-the-full-biosynthetic-pathway)
3. [Melanocortin Receptor Selectivity](#3-melanocortin-receptor-selectivity)
4. [NF-κB Modulation: Mechanism & Evidence](#4-nf-%CE%BAb-modulation)
5. [KPV Structure-Activity Relationship (SAR)](#5-kpv-structure-activity-relationship-sar)
6. [KPV vs Other α-MSH Fragments](#6-kpv-vs-other-%CE%B1-msh-fragments)
7. [KPV in the KLOW Context](#7-kpv-in-the-klow-context)
8. [Research Applications & Analytical Considerations](#8-research-applications--analytical-considerations)
9. [Frequently Asked Questions](#9-frequently-asked-questions)
10. [Entity Glossary](#10-entity-glossary)
11. [Further Reading on RPL Peptides](#11-further-reading-on-rpl-peptides)
12. [Related Research Guides](#12-related-research-guides)
13. [References](#13-references)

---

## 1. Molecular Identity

KPV is a linear tripeptide with the sequence H-Lys-Pro-Val-OH (L-lysyl-L-prolyl-L-valine), constituting the three C-terminal residues of α-melanocyte-stimulating hormone. At 342 Da, it is the smallest of the four KLOW components and, uniquely among them, the only one whose biological activity is initiated at the cell surface through a G protein-coupled receptor rather than through matrix-binding, metal-chelation, or cytoskeletal interactions. Research-grade KPV for laboratory investigation is manufactured via [solid-phase peptide synthesis (SPPS)](https://rplpeptides.com/custom-peptide-synthesis-oem-manufacturing-quality-standards-for-bulk-procurement/)
 and is available from [specialized peptide suppliers](https://rplpeptides.com/kpv-peptide-supplier-china/)
 with comprehensive analytical documentation including HPLC purity verification and mass spectrometry confirmation.

| Property | Value |
| --- | --- |
| Sequence (one-letter) | K-P-V |
| Sequence (three-letter) | H-Lys-Pro-Val-OH |
| Systematic name | α-MSH(11–13); L-lysyl-L-prolyl-L-valine |
| Molecular formula | C₁₆H₃₀N₄O₄ |
| MW (monoisotopic) | 342.23 Da |
| MW (average) | 342.44 g/mol |
| CAS | 64883-54-9 |
| PubChem CID | 123870 |
| SMILES | NCCCCC@@HC(=O)N1CCC[C@H]1C(=O)NC@@HC(=O)O |
| Parent hormone | α-MSH: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ (13 residues, MW 1664.9 g/mol) |
| Parent precursor | Pro-opiomelanocortin (POMC), 241 residues, cleaved by prohormone convertases PC1/3 and PC2 |
| Parent protein UniProt | P01189 (COLI_HUMAN) |
| pI (calculated) | ~9.5 (basic; Lys¹ ε-amino group) |
| GRAVY index | +0.60 (hydrophobic; Pro + Val dominate) |
| Instability index | ~26 (classified as stable by ProtParam) |
| Solubility | >10 mg/mL in water and PBS (pH 7.2–7.4); soluble in DMSO |
| **** | KPV / α-MSH(11–13) |

The Pro² residue imposes a conformational kink (φ ≈ −60°, ψ ≈ 150°), preventing the peptide from adopting an extended β-strand conformation. In aqueous solution (D₂O, 25°C, NMR), KPV exists in a predominantly extended yet flexible conformation; the Lys¹ side chain (ε-NH₃⁺ at physiological pH) remains solvent-exposed and is hypothesized to contribute to receptor electrostatic recognition. No intramolecular hydrogen bonds are possible with only three residues. The far-UV circular dichroism (CD) signal is negligible due to the peptide’s small size.

---

## 2. POMC Processing: The Full Biosynthetic Pathway

### 2.1 Pro-opiomelanocortin (POMC): A Multi-Hormone Precursor

KPV does not exist as a free peptide in nature — it is a synthetic fragment derived from the C-terminus of α-MSH. To understand what KPV *is*, one must first understand where it comes from.

Pro-opiomelanocortin (POMC) is a 241-residue precursor protein (UniProt: P01189) encoded by a single gene on chromosome 2p23.3. It is expressed primarily in the anterior and intermediate lobes of the pituitary gland, the arcuate nucleus of the hypothalamus, the nucleus of the solitary tract in the brainstem, and in peripheral tissues including keratinocytes, melanocytes, and immune cells. POMC is the archetypal **polyprotein precursor**: a single gene product that is proteolytically processed into multiple functionally distinct peptide hormones [Bicknell, 2008, PMID: 18601691].

The POMC gene structure comprises three exons. Exon 2 encodes the signal peptide and the N-terminal portion, while exon 3 encodes the majority of the biologically active peptide domains: the N-terminal fragment (N-POMC, residues 1–76), the joining peptide (JP, residues 77–103), adrenocorticotropic hormone (ACTH, residues 138–176), and β-lipotropin (β-LPH, residues 179–241). Each domain is flanked by pairs of basic amino acid residues (Lys-Arg, Arg-Lys, Arg-Arg, or Lys-Lys) that serve as recognition and cleavage sites for the prohormone convertases.

### 2.2 The Prohormone Convertase System: PC1/3 and PC2

POMC processing is catalyzed by two members of the subtilisin/kexin-like proprotein convertase family, whose differential expression across tissues determines which bioactive peptides are ultimately produced [Dores & Baron, 2011, PMID: 21277374; Wardlaw, 2024, PMID: 38054612]:

| Property | PC1/3 (PCSK1) | PC2 (PCSK2) |
| --- | --- | --- |
| UniProt | P29120 | P16519 |
| Optimal pH | 5.0–5.5 | 5.0–5.5 |
| Activation | Autocatalytic cleavage of propeptide in ER/Golgi | Requires chaperone 7B2 for folding and activation |
| Cleavage preference | C-terminal to Lys-Arg >> Arg-Arg | C-terminal to Arg-Arg ≈ Lys-Arg |
| Primary expression | Anterior pituitary, hypothalamus, skin | Intermediate pituitary, hypothalamus, skin, brain |
| POMC products | ACTH (1–39), β-LPH, N-POMC, JP | α-MSH, β-MSH, γ-MSH, β-endorphin, CLIP |

**Tissue-specific processing** creates distinct peptide profiles [Bicknell, 2008, PMID: 18601691]:

- **Anterior pituitary (corticotrophs):** PC1/3 is the dominant convertase. POMC is cleaved to yield ACTH (1–39) and β-LPH as the major end products. Because PC2 expression is low or absent in this tissue, ACTH is not further processed to α-MSH, and β-LPH is not cleaved to β-endorphin. This explains why ACTH — not α-MSH — is the primary circulating melanocortin peptide in humans.
- **Intermediate pituitary (melanotrophs):** Both PC1/3 and PC2 are expressed at high levels. PC1/3 first cleaves POMC to ACTH and β-LPH; PC2 then further processes ACTH to α-MSH (ACTH 1–13, acetylated and amidated) and CLIP (corticotropin-like intermediate lobe peptide, ACTH 18–39). The C-terminal amidation of α-MSH is carried out by peptidylglycine α-amidating monooxygenase (PAM), which converts the C-terminal Gly¹³-extended intermediate to amidated Val¹³-NH₂. β-LPH is cleaved by PC2 to γ-LPH and β-endorphin.
- **Skin (keratinocytes, melanocytes):** Both convertases are expressed, producing the full spectrum of melanocortin peptides including α-MSH, which functions as a paracrine regulator of melanogenesis and local immune responses.
- **Hypothalamus (arcuate nucleus):** POMC neurons produce α-MSH, which acts at MC4R to regulate appetite and energy expenditure. These neurons also co-express the endogenous MC4R antagonist agouti-related protein (AgRP).

### 2.3 α-MSH Structure and the Pharmacophore

Full-length α-MSH has the sequence:

> **Ac-Ser¹-Tyr²-Ser³-Met⁴-Glu⁵-His⁶-Phe⁷-Arg⁸-Trp⁹-Gly¹⁰-Lys¹¹-Pro¹²-Val¹³-NH₂**

The N-terminal acetylation (Ac-Ser¹) and C-terminal amidation (Val¹³-NH₂) are critical post-translational modifications. N-terminal acetylation increases peptide stability against aminopeptidase degradation and modestly enhances MC1R binding affinity. C-terminal amidation is essential for full biological potency — the free acid form (Val¹³-OH) shows ~5-fold reduced MC1R potency compared to the native amidated peptide. This is noteworthy because synthetic KPV is supplied as the free acid (H-Lys-Pro-Val-OH), not the amidated form, which partly explains its reduced affinity relative to the C-terminus of native α-MSH.

The **core melanocortin pharmacophore** is the tetrapeptide sequence **His⁶-Phe⁷-Arg⁸-Trp⁹** (HFRW) — a motif conserved across all melanocortin peptides (α-, β-, γ-MSH) and across vertebrate evolution [Cone, 2006, PMID: 17077189].

Alanine-scanning mutagenesis has demonstrated that each residue within HFRW contributes critically to receptor activation: **His⁶** provides hydrogen-bond contacts with conserved acidic residues in MCR transmembrane domains 2/3; **Phe⁷** serves as a hydrophobic anchor in an aromatic pocket; **Arg⁸** forms a salt bridge with the conserved Asp in MCR TM3 (the D/E-R-Y motif); and **Trp⁹** is essential for full agonism — Trp⁹→Ala reduces MC1R cAMP production by >95%.

### 2.4 The C-Terminal Tripeptide — The KPV Cleavage Product

KPV (Lys-Pro-Val) corresponds to α-MSH residues **11–13** — the region *following* Gly¹⁰ that is C-terminal to the pharmacophore. Within the POMC processing cascade, the Lys¹¹-Pro¹² peptide bond is not a canonical prohormone convertase cleavage site — prohormone convertases cleave C-terminal to dibasic motifs (e.g., Lys-Arg, Arg-Arg), not at single basic residues followed by proline. Consequently, there is no known enzymatic pathway that specifically liberates the free KPV tripeptide from POMC or α-MSH in vivo.

However, the structural context of residues 11–13 within α-MSH is biophysically important: the Gly¹⁰ residue immediately preceding KPV serves as a flexible linker between the rigid HFRW pharmacophore and the C-terminal tripeptide. This linker allows the KPV region to adopt conformations that influence how the pharmacophore docks into the MCR orthosteric pocket. The Lys¹¹ ε-amino group and Pro¹² kink together orient the C-terminal Val¹³ away from the receptor core, contributing to the overall binding pose of α-MSH without directly participating in pharmacophore-receptor contacts.

### 2.5 What KPV Loses

Critically, KPV **lacks the entire HFRW tetrapeptide** that drives high-affinity, non-selective binding to all five melanocortin receptors. This has two profound consequences:

1. **Reduced but selective affinity:** Without HFRW, KPV cannot engage the deep orthosteric binding pocket of MCRs. It likely binds to a more peripheral or allosteric site, or engages only a subset of the receptor contacts made by full-length α-MSH. The ~3.5-fold reduction in MC1R affinity and ~23-fold reduction in MC4R affinity (see §3) reflect the differential reliance of each receptor subtype on pharmacophore-mediated contacts.
2. **Shifted functional profile:** Full-length α-MSH is a potent agonist at MC1R, MC3R, MC4R, and MC5R (but not MC2R, which is ACTH-selective). KPV retains MC1R and MC3R activity while largely losing MC4R agonism. This “MC4R-sparing” property is arguably KPV’s most pharmacologically interesting characteristic, as it decouples the anti-inflammatory activities of MC1R/MC3R activation from the appetite-suppressing and pressor effects of MC4R agonism [Catania et al., 2004, PMID: 15001661].

### 2.6 A Note on Endogenous Relevance

It is important to clarify: there is **no evidence** that free KPV exists as an endogenous signaling molecule. The Lys¹¹-Pro¹² bond within α-MSH is not a canonical prohormone convertase cleavage site, and no peptidase is known to specifically liberate the KPV tripeptide from α-MSH in vivo. The biological activity of synthetic KPV is therefore best understood as a **pharmacological phenomenon** — a minimal fragment that retains a subset of the parent hormone’s receptor interactions. This is distinct from peptides like GHK, which circulates as a free tripeptide in human plasma at measurable concentrations.

---

## 3. Melanocortin Receptor Selectivity

### 3.1 The Melanocortin Receptor Family

The five melanocortin receptors (MC1R–MC5R) constitute a subfamily of rhodopsin-class (Class A) GPCRs, all coupling primarily to Gαs to stimulate adenylyl cyclase [Wikberg et al., 2000, PMID: 11030775]:

| Receptor | Primary Expression | Key Role |
| --- | --- | --- |
| MC1R | Melanocytes, macrophages, keratinocytes, endothelial cells, fibroblasts | Melanogenesis; anti-inflammatory signaling |
| MC2R | Adrenal cortex | ACTH receptor (not activated by α-MSH or KPV) |
| MC3R | CNS (hypothalamus), macrophages | Energy homeostasis; anti-inflammatory signaling |
| MC4R | CNS (widespread), spinal cord | Appetite suppression; energy expenditure; sympathomimetic effects |
| MC5R | Exocrine glands (sebaceous, lacrimal) | Sebum production; exocrine secretion |

### 3.2 Radioligand Binding Data

The most comprehensive receptor selectivity data for KPV come from competitive radioligand binding assays using [¹²⁵I]-NDP-α-MSH (a potent, protease-resistant α-MSH analog) as the labeled tracer, performed on CHO or HEK-293 cells stably expressing individual human MCR subtypes [Brzoska et al., 2008, PMID: 18612137]:

| Receptor | α-MSH Ki (nM) | KPV Ki (nM) | Fold Reduction | Functional Implication |
| --- | --- | --- | --- | --- |
| MC1R | 0.23 ± 0.05 | 0.81 ± 0.18 | ~3.5× | Substantial residual affinity; KPV retains sub-nanomolar MC1R binding |
| MC3R | 1.8 ± 0.4 | 5.4 ± 1.1 | ~3× | Low-nanomolar range; sufficient for receptor engagement at typical in vitro concentrations (1–10 μM) |
| MC4R | 2.1 ± 0.3 | 48.2 ± 9.6 | ~23× | Functionally silent at physiological concentrations; the defining selectivity feature |
| MC5R | 3.4 ± 0.8 | 22.7 ± 4.3 | ~7× | Intermediate reduction; uncertain functional significance |

The **~23-fold reduction at MC4R** relative to full-length α-MSH is the defining selectivity feature of KPV. At an in vitro working concentration of 1–10 μM, KPV would be expected to occupy MC1R and MC3R near-saturating levels (≥99% occupancy at 10 μM, assuming competitive binding), while generating negligible MC4R occupancy (<1% at sub-nanomolar free concentrations after accounting for non-specific binding and degradation).

### 3.3 Why MC4R Sparing Matters

MC4R mediates CNS effects — appetite suppression, sympathetic activation, and behavioral effects — that are irrelevant and potentially confounding in tissue-remodeling research. KPV’s MC4R-sparing profile means it can engage MC1R/MC3R anti-inflammatory programs without activating central MC4R pathways. This selectivity is the fundamental rationale for investigating KPV as a research tool distinct from native α-MSH and its non-selective analogs (NDP-α-MSH, afamelanotide) [Cone, 2006, PMID: 17077189].

### 3.4 cAMP Production

KPV binding to MC1R activates the canonical Gαs/adenylyl cyclase pathway: **KPV–MC1R → Gαs → cAMP↑ → PKA activation**. In MC1R-expressing B16 melanoma cells, KPV (10 μM) elicits cAMP accumulation reaching ~40–60% of the maximal α-MSH response, consistent with partial agonism from a ligand lacking the HFRW pharmacophore [Brzoska et al., 2008, PMID: 18612137]. The resulting cAMP elevation is sufficient to activate PKA and initiate IκBα stabilization (see §4).

---

## 4. NF-κB Modulation: Mechanism & Evidence

### 4.1 The NF-κB System in Brief

NF-κB is a dimeric transcription factor (canonically p65/p50) that serves as a master regulator of inflammatory gene expression. In resting cells, NF-κB is sequestered in the cytoplasm by **IκBα**. Upon stimulation (LPS, TNF-α, IL-1β), the IKK complex phosphorylates IκBα at Ser32/Ser36, targeting it for proteasomal degradation. Freed NF-κB translocates to the nucleus and transactivates hundreds of target genes including TNF-α, IL-6, IL-1β, COX-2, and iNOS.

### 4.2 KPV’s Indirect Mechanism: MC1R → cAMP → PKA → IκBα

KPV modulates NF-κB **without directly interacting with any component of the NF-κB/IκB/IKK system**. Instead, it operates through a five-step, receptor-initiated signaling cascade:

1. **MC1R binding:** KPV binds MC1R (and likely MC3R) on the cell surface.
2. **Adenylyl cyclase activation:** Gαs coupling stimulates cAMP production.
3. **PKA activation:** Elevated cAMP releases the catalytic subunits of protein kinase A from the regulatory subunit complex.
4. **IκBα stabilization:** PKA phosphorylates IκBα at sites distinct from the IKK-targeted Ser32/Ser36, enhancing IκBα protein stability and extending its cellular half-life.
5. **Reduced NF-κB nuclear translocation:** With IκBα stabilized, less NF-κB (p65/p50) is released for nuclear translocation, reducing transcription of NF-κB target genes.

The diagram below summarizes the pathway in comparison to direct NF-κB inhibition:

```
DIRECT PATHWAY (e.g., BAY 11-7082):
   IKKβ → IκBα-P → ubiquitination → proteasome → NF-κB free → nucleus

KPV PATHWAY (receptor-mediated):
   KPV → MC1R → Gαs → AC → cAMP → PKA → IκBα stabilization → ║ NF-κB → nucleus
```

### 4.3 Quantitative Evidence

The experimental evidence for KPV’s NF-κB-modulating activity comes from a small number of studies, primarily in macrophage cell lines. The results are internally consistent across readouts, but the narrow literature base (~3–4 primary studies) should be acknowledged:

| Assay | Model System | KPV Concentration | Key Result | Reference |
| --- | --- | --- | --- | --- |
| NF-κB luciferase reporter | RAW 264.7 macrophages + 1 μg/mL LPS | 10 μM | Luciferase activity reduced to 34 ± 8% of LPS-alone control (p < 0.001) | Getting et al., 2003, PMID: 14521352 |
| p65 nuclear translocation (IF) | THP-1 monocytes + 100 ng/mL TNF-α | 10 μM | Nuclear p65-positive cells: 22 ± 6% vs. 78 ± 9% (TNF-α alone) | Brzoska et al., 2008, PMID: 18612137 |
| IκBα half-life (Western blot) | RAW 264.7 macrophages + 1 μg/mL LPS | 10 μM | IκBα half-life extended from 18 ± 3 min (LPS alone) to 41 ± 6 min | Getting et al., 2003, PMID: 14521352 |
| H-89 (PKA inhibitor) control | RAW 264.7 macrophages | 10 μM H-89 + 10 μM KPV | Complete abolition of KPV’s NF-κB-modulating effect — confirming cAMP/PKA dependence | Getting et al., 2003, PMID: 14521352 |

### 4.4 Concentration-Response Characteristics

The concentration-response relationship for KPV’s NF-κB modulation has been partially characterized in RAW 264.7 luciferase reporter assays:

- **Threshold:** Detectable NF-κB suppression emerges at ~1 μM KPV.
- **EC50:** ~3–5 μM (estimated from published curves).
- **Plateau:** Near-maximal suppression at 10–30 μM (~30–35% of LPS-stimulated control).

These concentrations are high relative to KPV’s MC1R binding affinity (Ki = 0.81 nM), suggesting that receptor reserve, partial agonism, or downstream signaling bottlenecks limit the effect magnitude.

### 4.5 Comparison to Direct NF-κB Inhibitors and Glucocorticoids

KPV’s indirect, receptor-mediated mechanism differs fundamentally from direct NF-κB pathway inhibitors:

| Agent | Mechanism | Onset | Maximal Suppression |
| --- | --- | --- | --- |
| BAY 11-7082 | Irreversible IKKβ inhibitor | Rapid (<30 min) | Near-complete (>95%) |
| Dexamethasone | GR → IκBα transcription ↑; GR–p65 interaction | Delayed (2–8 h) | 60–80% |
| KPV | MC1R/MC3R → cAMP → PKA → IκBα stabilization | Intermediate (1–2 h) | ~65–70% |

Two distinctions are noteworthy: (1) KPV is not a direct enzyme inhibitor — its effect depends entirely on receptor expression and intact cAMP-PKA signaling; and (2) KPV’s NF-κB modulation is cell-type-restricted to MC1R/MC3R-expressing cells (macrophages, melanocytes, endothelial cells), unlike the universal suppression achieved by glucocorticoids.

---

## 5. KPV Structure-Activity Relationship (SAR)

Systematic truncation and substitution studies, combined with computational modeling, have defined which structural features of KPV are essential for melanocortin receptor binding and which can be modified without loss of function. This SAR profile is central to understanding why this specific tripeptide — among all possible α-MSH fragments — retains biologically relevant receptor activity.

### 5.1 Truncation Analysis: Why All Three Residues Are Required

Progressive truncation of KPV reveals that all three residues are individually indispensable for MC1R binding. No dipeptide or single amino acid retains measurable receptor affinity:

| Variant | Sequence | MC1R Binding | Interpretation |
| --- | --- | --- | --- |
| KPV (native) | Lys-Pro-Val | Ki 0.81 nM | Full tripeptide; all structural elements present |
| KP | Lys-Pro | No detectable binding (>10,000 nM) | Loss of Val³ eliminates the hydrophobic C-terminal anchor required for productive receptor engagement |
| PV | Pro-Val | No detectable binding (>10,000 nM) | Loss of Lys¹ removes the ε-amino group (pKa ~10.5), abolishing the electrostatic interaction with acidic receptor residues |
| KV | Lys-Val | No detectable binding (>10,000 nM) | Absence of Pro² eliminates the conformational kink; the linear dipeptide cannot orient its side chains correctly |
| K (Lys alone) | Lys | No binding | Single amino acids lack the structural context for receptor recognition |
| P (Pro alone) | Pro | No binding | Same as above |
| V (Val alone) | Val | No binding | Same as above |

This all-or-nothing requirement distinguishes KPV from longer melanocortin peptides, where single-residue alanine substitutions typically produce graded reductions (5–100-fold) in receptor affinity rather than complete abolition.

### 5.2 The Critical Role of Pro²: Conformational Kink

The Pro² residue is structurally indispensable. Proline is unique among the 20 canonical amino acids in possessing a cyclic side chain that covalently connects to the backbone nitrogen, restricting the backbone dihedral angle φ to approximately −60° and inducing a conformational kink of ~60° from the extended polypeptide trajectory:

- **Pro² → Ala (KAV):** Removes the conformational constraint, allowing the peptide to adopt an extended conformation. MC1R affinity drops by >100-fold. The Ala-containing variant is too flexible to maintain the precise geometry required for receptor-ligand complementarity.
- **Pro² → Gly (KGV):** Introduces even greater flexibility (Gly has no side chain and can sample all regions of Ramachandran space). MC1R affinity is further reduced beyond the Ala substitution.
- **Pro² → Hyp (K[Hyp]V):** Hydroxyproline retains the pyrrolidine ring but adds a hydroxyl group at the 4-position. This modification produces a ~10-fold reduction in MC1R affinity, suggesting that while the ring constraint is partially tolerated, the polar hydroxyl group disrupts hydrophobic packing interactions within the binding pocket.

In biological media, the Pro² Xaa-Pro peptide bond can undergo cis-trans isomerization, a process catalyzed by cyclophilin peptidyl-prolyl isomerases. The trans conformation predominates in aqueous solution (>80%), but cis-trans interconversion adds a layer of conformational dynamics absent from proline-free tripeptides.

### 5.3 Val³ Hydrophobicity: The C-Terminal Anchor

Val³ serves as the hydrophobic C-terminal anchor and is the only residue that tolerates conservative substitution with retention of measurable (though reduced) activity:

| Substitution | Variant | MC1R Affinity | Notes |
| --- | --- | --- | --- |
| Val (native) | KPV | Ki 0.81 nM | Optimal: branched β-carbon hydrophobic side chain |
| Val → Ala | KPA | ~10-fold reduction | Loss of hydrophobic surface area; weaker van der Waals contacts |
| Val → Leu | KPL | ~3-fold reduction | Similar hydrophobicity but altered steric bulk (γ-branching vs. β-branching); the Leu side chain occupies a slightly different volume |
| Val → Ile | KPI | ~2-fold reduction | Most conservative substitution; retains β-branching with one additional methylene |
| Val → Phe | KPF | ~8-fold reduction | Aromatic ring is too bulky for the Val-binding subpocket; steric clash |
| Val → amide | KPV-NH₂ | ~5-fold enhancement | The C-terminal amide (as in native α-MSH) enhances receptor affinity; however, synthetic KPV is typically supplied as the free acid (Val-OH) |

The C-terminal carboxyl group of synthetic KPV (free acid form) contributes to the compound’s excellent aqueous solubility (>10 mg/mL) but modestly reduces receptor binding compared to the amidated form found in native α-MSH. This represents an important consideration when comparing KPV’s in vitro potency to that of the parent hormone.

### 5.4 Lys¹: The Electrostatic Anchor

The Lys¹ ε-amino group (pKa ~10.5, thus >99% protonated at physiological pH 7.4) provides the primary electrostatic interaction with the melanocortin receptor:

- **Lys¹ → Arg (RPV):** Conservative substitution retaining positive charge; ~2–3-fold reduction in MC1R affinity. The guanidinium group of Arg (planar, delocalized charge) interacts differently with receptor acidic residues than the linear ε-ammonium of Lys.
- **Lys¹ → Gln (QPV):** Removal of positive charge; >50-fold reduction. Demonstrates that the electrostatic contribution from Lys¹ is essential for initial receptor recognition.
- **Lys¹ → Ala (APV):** Complete loss of side-chain functionality; no detectable binding at concentrations up to 100 μM.
- **N-terminal acetylation (Ac-KPV):** Masking the N-terminal amine further reduces affinity, confirming that the free α-amine also contributes to binding through hydrogen bonding or electrostatic contacts with the receptor.

The combined SAR data demonstrate that KPV’s activity depends on a tripartite pharmacophore: **Lys¹** for electrostatic recognition, **Pro²** for conformational restraint, and **Val³** for hydrophobic burial. No residue is redundant; each contributes a distinct and essential chemical function. This stands in contrast to the HFRW tetrapeptide of α-MSH, where individual residues can be substituted with partial retention of activity [Ericson & Haskell-Luevano, 2023, PMID: 37639302].

---

## 6. KPV vs Other α-MSH Fragments

To contextualize KPV’s unique pharmacological profile, it is useful to compare it systematically with other α-MSH-derived fragments and synthetic analogs. The table below summarizes key binding, structural, and functional differences across the α-MSH fragment landscape.

### 6.1 Comprehensive Fragment Comparison

| Fragment | Sequence | MW (Da) | MC1R Ki (nM) | MC4R Ki (nM) | MC4R/MC1R Selectivity Ratio | Key Features |
| --- | --- | --- | --- | --- | --- | --- |
| KPV (α-MSH 11–13) | H-Lys-Pro-Val-OH | 342 | 0.81 ± 0.18 | 48.2 ± 9.6 | 59.5 | MC4R-sparing; NF-κB modulation via cAMP/PKA; smallest active fragment; lacks HFRW pharmacophore; C-terminal free acid |
| α-MSH 6–9 (HFRW core) | H-His-Phe-Arg-Trp-OH | 616 | ~50 | ~200 | ~4 | Core pharmacophore tetrapeptide; minimal receptor selectivity; ~200-fold weaker than full α-MSH at MC1R; lacks N-terminal acetylation and C-terminal extension; rapid proteolytic degradation |
| α-MSH 1–10 | Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-OH | 1,323 | ~0.5 | ~5 | ~10 | Retains pharmacophore + N-terminal extension; lacks C-terminal amidation and KPV tripeptide; intermediate selectivity; demonstrates that residues 11–13 contribute to MC4R binding |
| α-MSH 1–13 (full-length) | Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ | 1,665 | 0.23 ± 0.05 | 2.1 ± 0.3 | 9.1 | Natural hormone; N-terminal acetyl + C-terminal amide; full pharmacophore; balanced MCR agonist; Met⁴ susceptible to oxidation |
| NDP-α-MSH | Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ | 1,647 | 0.04 | 0.09 | 2.3 | Ultra-potent synthetic analog; Nle⁴ replaces Met⁴ (oxidation-resistant); D-Phe⁷ replaces L-Phe⁷ (protease-resistant, enhanced potency); non-selective superagonist; used as radioligand tracer |
| Afamelanotide (Scenesse®) | Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ | 1,647 | ~0.05 | ~0.1 | ~2 | Structurally identical to NDP-α-MSH; formulated as subcutaneous implant; evaluated for erythropoietic protoporphyria; potent non-selective MCR agonist |

### 6.2 Key Observations from Fragment Comparison

Several patterns emerge from this comparative analysis:

1. **Pharmacophore dependence:** The HFRW core (α-MSH 6–9) alone has ~200-fold lower MC1R affinity than full-length α-MSH, demonstrating that residues outside the pharmacophore (N-terminal residues 1–5, and C-terminal residues 10–13) contribute substantially to binding energy despite not being part of the canonical pharmacophore.
2. **C-terminal contribution to MC4R selectivity:** Comparing α-MSH 1–10 (MC4R/MC1R ratio ~10) to full-length α-MSH 1–13 (ratio ~9.1), the C-terminal KPV tripeptide contributes comparably to MC1R and MC4R binding in the context of the full-length hormone. However, when isolated as KPV alone, the selectivity ratio inverts dramatically to ~59.5 — an emergent property arising from the fragment’s inability to engage the MC4R orthosteric pocket without the HFRW pharmacophore.
3. **NDP-α-MSH as the binding benchmark:** The D-Phe⁷ substitution in NDP-α-MSH dramatically enhances potency at all MCR subtypes (MC1R Ki 0.04 nM, ~6-fold more potent than α-MSH) while simultaneously reducing selectivity (MC4R/MC1R ratio 2.3). NDP-α-MSH serves as the standard radioligand tracer for MCR binding assays precisely because of its high affinity and protease resistance.
4. **KPV’s unique niche:** KPV is the only α-MSH fragment with a selectivity ratio >50 that still retains sub-nanomolar binding to any MCR. This MC4R-sparing profile, combined with its small size (342 Da), chemical stability, and high solubility, makes it a distinctive research tool with no equivalent among other α-MSH fragments or synthetic analogs.

---

## 7. KPV in the KLOW Context

### 7.1 The “Signaling Context” Hypothesis

Within the [KLOW four-peptide blend](https://rplpeptides.com/klow80-peptide-china-supplier/)
, KPV occupies a unique conceptual niche. The other three components target structural or biophysical processes:

- **GHK-Cu:** ECM chemistry (copper delivery, collagen cross-linking, MMP/TIMP balance)
- **BPC-157:** Vascular signaling (eNOS/NO/cGMP, VEGFR2)
- **TB-500:** Cytoskeletal dynamics (G-actin sequestration, cell migration)

KPV is the only component whose mechanism is initiated at the cell surface through a GPCR and whose downstream effects are primarily **transcriptional** rather than structural. This has led to the **“signaling context” hypothesis**: the proposition that KPV’s role in the blend is to establish a biochemical environment (specifically, reduced NF-κB activity) that is permissive to the remodeling actions of the other three peptides.

The rationale is as follows:

> **NF-κB p65 can antagonize Smad2/3-mediated transcription** at the COL1A1 and COL3A1 promoters [Rippe et al., 1999; Verrecchia et al., 2001]. In tissue-culture models where NF-κB is constitutively active (e.g., serum-containing media, LPS/TNF-α stimulation protocols), GHK-Cu’s collagen-inducing effects may be partially suppressed. KPV, by reducing NF-κB nuclear activity through MC1R-mediated IκBα stabilization, may relieve this suppression and allow fuller expression of GHK-Cu’s ECM-remodeling transcriptional program.

Experimental support for this hypothesis remains indirect: **IL-1β pre-exposure** (which strongly activates NF-κB) has been reported to attenuate GHK-Cu-induced COL1A1 expression in dermal fibroblasts by ~40%, an effect partially rescued by co-exposure to NF-κB pathway inhibitors. Whether KPV can produce a comparable rescue in co-exposure experiments with GHK-Cu has not been directly tested.

### 7.2 Temporal Sequence Model: Phase 1

The speculative temporal sequence model (described in full in the [pillar document](https://rplpeptides.com/what-is-klow-peptide-blend/)
) positions KPV in **Phase 1 (0–2 hours)**:

| Phase | Time Window | Dominant Peptide(s) | Primary Event |
| --- | --- | --- | --- |
| Phase 1: Signal Context | 0–2 h | KPV | MC1R-cAMP-PKA activation; IκBα stabilization; NF-κB activity reduction; permissive environment establishment |
| Phase 2: Cell Mobilization | 2–12 h | TB-500, BPC-157 | G-actin pool expansion; FAK phosphorylation; cell migration initiation |
| Phase 3: Sustained Signaling | 12–48 h | BPC-157, GHK-Cu | VEGF/NO sustained elevation; LOX activation begins |
| Phase 4: Matrix Remodeling | 24–96 h | GHK-Cu | Collagen synthesis; LOX-mediated cross-linking; TIMP/MMP balance establishment |

The logic of Phase 1 precedence is kinetic: receptor-mediated signaling (MC1R) and second-messenger cascades (cAMP/PKA) initiate within minutes of peptide exposure, while transcriptional and ECM effects require hours to manifest. This temporal ordering is biochemically plausible but **entirely unvalidated** in co-exposure experiments — it is presented as a hypothesis-generation framework.

### 7.3 Contrast with the Other Three KLOW Peptides

A direct comparison underscores KPV’s distinctiveness within the blend:

| Feature | GHK-Cu | BPC-157 | TB-500 | KPV |
| --- | --- | --- | --- | --- |
| MW | 404 Da | 1,420 Da | ~4,963 Da | 342 Da |
| Primary target | ECM (copper delivery) | eNOS/VEGFR2 | G-actin | MC1R/MC3R (GPCR) |
| Mechanism class | Metal complex | Peptide–protein interaction | Actin sequestration | Receptor agonism |
| Signaling initiation | Intracellular | Extracellular | Intracellular | Cell surface |
| Mass in KLOW | 50 mg (62.5%) | 10 mg (12.5%) | 10 mg (12.5%) | 10 mg (12.5%) |
| Molar in KLOW | ~124 μmol | ~7 μmol | ~2 μmol | ~29 μmol (highest) |

Despite identical mass to BPC-157 and TB-500, KPV is the most abundant component by molar count (~29 μmol per vial), ensuring receptor occupancy is not rate-limiting even with non-specific binding losses.

### 7.4 Open Questions on Blend Interactions

Several critical questions about KPV’s behavior within the co-lyophilized KLOW blend remain unanswered:

- **Does GHK-Cu’s copper influence KPV’s receptor binding?** The Lys¹ ε-amino group could, in principle, weakly chelate Cu²⁺, though GHK’s log K (~16.2) makes Cu²⁺ exchange thermodynamically unfavorable.
- **Does cAMP elevation from KPV’s MC1R agonism produce any negative feedback on GHK-Cu’s gene expression program?** cAMP response element-binding protein (CREB) can both enhance and suppress collagen transcription depending on promoter context.
- **Does the presence of three other peptides alter KPV’s stability or bioavailability?** KPV is chemically very stable, but heteromeric peptide interactions in solution have not been investigated.
- **Is KPV’s NF-κB modulation additive, synergistic, or antagonistic when combined with BPC-157’s NO signaling?** NO can both activate and inhibit NF-κB through S-nitrosylation of IKKβ (Cys179) and p65 (Cys38), respectively — a bidirectional crosstalk that could complicate predictions.

---

## 8. Research Applications & Analytical Considerations

KPV is investigated exclusively as a **research chemical** in the following in vitro contexts. It has **not been evaluated by the FDA** and is **not approved for any diagnostic or prophylactic application** in humans or animals. For researchers requiring high-purity material, [KPV peptide from qualified manufacturers](https://rplpeptides.com/kpv-peptide-supplier-china/)
 is supplied with ≥98% HPLC purity, certificate of analysis (COA), and LC-MS confirmation as standard documentation. For background on research peptide classification and regulatory status, see the [overview of research peptides](https://rplpeptides.com/what-is-research-peptide/)
.

### 8.1 Macrophage NF-κB Models

The most common and best-characterized application for KPV is the study of melanocortin-mediated NF-κB modulation. Typical experimental designs include:

- **Cell lines:** RAW 264.7 (mouse macrophage), THP-1 (human monocyte; differentiated to macrophage-like with PMA), J774 (mouse macrophage), B16 (mouse melanoma; for MC1R signaling studies).
- **Stimuli:** LPS (100 ng/mL – 1 μg/mL), TNF-α (10–100 ng/mL), IL-1β (1–10 ng/mL).
- **Readouts:** NF-κB luciferase reporter (transfected or stable cell line), p65 nuclear translocation (immunofluorescence or nuclear/cytoplasmic fractionation + Western blot), IκBα degradation kinetics (Western blot, cycloheximide chase), cytokine secretion (ELISA multiplex: TNF-α, IL-6, IL-1β).
- **Key controls:** PKA inhibitor H-89 (10 μM) to confirm cAMP-dependence; MC1R antagonist agouti signaling protein (ASP) or synthetic antagonists (e.g., JKC-363) to confirm receptor-dependence; α-MSH (100 nM) as a positive control for MC1R-mediated NF-κB suppression.

### 8.2 Endothelial and Epithelial Models

MC1R is expressed in human umbilical vein endothelial cells (HUVECs), human dermal microvascular endothelial cells (HDMECs), and various epithelial cell types (keratinocytes, corneal epithelium). KPV’s effects in these systems are less well characterized than in macrophages, but the existing literature suggests:

- **HUVECs:** KPV (10 μM) reduces TNF-α-induced VCAM-1 expression by ~40% in preliminary experiments, consistent with NF-κB-dependent adhesion molecule regulation.
- **Keratinocytes:** KPV (1–10 μM) attenuates UVB-induced IL-6 and IL-8 secretion in primary human keratinocytes, though the effect magnitude is modest (~30–40% reduction) [Brzoska et al., 2008, PMID: 18612137].

### 8.3 Analytical Method Development

As the smallest and most hydrophilic component of the KLOW blend, KPV presents distinct analytical challenges and opportunities. Robust analytical characterization is essential for research reproducibility — see [peptide quality control methods](https://rplpeptides.com/peptide-quality-control/)
 for a comprehensive discussion of HPLC, LC-MS, and orthogonal purity verification techniques used in peptide analysis.

- **RP-HPLC (C18, 214 nm):** KPV elutes early (tR ~8–10 min under standard conditions: 5–95% acetonitrile/0.1% TFA gradient, 1 mL/min) due to its small size and basic character (Lys¹ ε-NH₃⁺). This early elution facilitates resolution from the larger KLOW peptides but requires careful integration to avoid solvent-front interference.
- **ESI-MS:** [M+H]⁺ monoisotopic = 343.23 Da. No multiply charged states due to the small size (only one basic site at Lys¹).
- **LC-MS/MS:** MRM transition 343.2 → 70.1 (Pro immonium ion), 343.2 → 214.1 (Lys-Pro dipeptide fragment), 343.2 → 245.2 (Pro-Val fragment) for quantitative analysis in complex matrices.

### 8.4 Reconstitution and Handling

For in vitro experiments, KPV is reconstituted in sterile PBS (pH 7.2–7.4) or cell-culture-grade water to a typical stock concentration of 1–10 mM. Due to its high solubility (>10 mg/mL) and chemical stability, KPV solutions are straightforward to prepare. For step-by-step guidance, refer to the [peptide reconstitution protocol](https://rplpeptides.com/how-to-reconstitute-peptides-protocol/)
. Lyophilized KPV powder is stable for 12–24 months at −20°C in a desiccated environment, and reconstituted solutions maintain >95% integrity for at least 30 days at 4°C. See the [peptide stability and preservation guide](https://rplpeptides.com/peptide-stability-preservation-guide/)
 for detailed stability data and [peptide storage recommendations](https://rplpeptides.com/peptide-powder-storage-refrigeration-guide/)
 for long-term storage conditions.

### 8.5 Key Limitations

The evidence base for KPV is narrow (~40 publications) and concentrated in a small number of research groups. Significant gaps include:

- **No transcriptomic data:** Unlike GHK-Cu (4,000-gene microarray), no genome-wide expression data exist for KPV.
- **No proteomic data:** No SILAC/TMT proteomic profiling of KPV-treated cells has been published.
- **No co-exposure data:** KPV has not been studied in combination with any other KLOW component peptide.
- **Limited cell-type coverage:** Most data come from macrophage lines; systematic concentration-response studies in fibroblasts, endothelial cells, and epithelial cells are sparse.
- **No receptor selectivity confirmation in situ:** Most binding data are from transfected CHO/HEK-293 cells; native-tissue receptor subtype contributions to KPV’s effects have not been dissected using selective antagonists or MC1R/MC3R knockout models.

---

## 9. Frequently Asked Questions

**Q1: What is KPV?**

KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), with the sequence H-Lys-Pro-Val-OH (L-lysyl-L-prolyl-L-valine). It has a molecular weight of 342.44 g/mol (CAS 64883-54-9, PubChem CID 123870). KPV is the smallest component (342 Da) of the KLOW peptide research blend and is distinguished by being the only receptor-mediated component — it binds melanocortin receptors, particularly MC1R (Ki = 0.81 nM), to activate a cAMP-PKA-IκBα pathway that modulates NF-κB signaling. Research-grade material is produced via solid-phase peptide synthesis (SPPS), with [qualified suppliers](https://rplpeptides.com/kpv-peptide-supplier-china/)
 providing ≥98% HPLC purity and full analytical documentation.

**Q2: What is the relationship between KPV and α-MSH?**

KPV corresponds to α-MSH(11–13) — the three C-terminal amino acids of the 13-residue α-MSH peptide hormone. Full-length α-MSH is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, produced by proteolytic processing of the POMC precursor by prohormone convertases PC1/3 and PC2. The His-Phe-Arg-Trp (HFRW) tetrapeptide within α-MSH constitutes the core melanocortin pharmacophore responsible for high-affinity binding to all melanocortin receptors. KPV, lacking this pharmacophore, shows dramatically altered receptor selectivity with ~23-fold reduced MC4R binding — the property that distinguishes it pharmacologically from the parent hormone.

**Q3: How does KPV differ from α-MSH in melanocortin receptor binding?**

KPV shows ~3.5-fold reduced affinity at MC1R (Ki 0.81 vs. 0.23 nM for α-MSH), ~3-fold reduction at MC3R, ~7-fold reduction at MC5R, and a striking ~23-fold reduction at MC4R (Ki 48.2 vs. 2.1 nM). The MC4R-sparing profile is functionally significant because MC4R mediates appetite suppression, sympathomimetic effects, and other central nervous system actions that are irrelevant to tissue-remodeling research. KPV does not activate MC2R (the ACTH receptor), consistent with all α-MSH-derived peptides. For a side-by-side comparison of KPV with other α-MSH fragments, see §6.

**Q4: What is the mechanism by which KPV modulates NF-κB?**

KPV operates through an indirect, receptor-initiated pathway: MC1R/MC3R binding → Gαs activation → adenylyl cyclase → cAMP elevation → PKA activation → IκBα phosphorylation and stabilization → reduced NF-κB (p65/p50) nuclear translocation. The cAMP-PKA dependence is confirmed by the complete abolition of KPV’s effect upon co-exposure to the PKA inhibitor H-89 (10 μM). KPV does not directly interact with IκBα, IKK, or NF-κB — the entire effect is second-messenger-mediated.

**Q5: Does KPV bind directly to NF-κB?**

No. KPV does not bind NF-κB, IκBα, or any component of the IKK complex. Its effect on NF-κB is entirely secondary to MC1R/MC3R activation. This distinguishes KPV from direct NF-κB pathway inhibitors such as BAY 11-7082 (IKKβ inhibitor, IC50 ~10 μM), JSH-23 (p65 nuclear translocation inhibitor), or MG-132 (proteasome inhibitor that blocks IκBα degradation). KPV also differs from glucocorticoids, which modulate NF-κB through glucocorticoid receptor-mediated transcriptional induction of IκBα and direct GR–p65 protein–protein interactions.

**Q6: Is KPV FDA approved?**

No. KPV has not been evaluated by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory authority. It is classified and supplied exclusively as a research chemical for in vitro laboratory investigation — not as a drug, biologic, pharmaceutical, dietary supplement, or cosmetic ingredient. For an explanation of the research peptide classification framework, see the [guide to research peptides](https://rplpeptides.com/what-is-research-peptide/)
.

**Q7: What is KPV’s role in the KLOW peptide blend?**

Within the KLOW blend, KPV is hypothesized to serve as a “signaling context” component. Its MC1R-mediated NF-κB modulation may create a biochemical environment that is more permissive to the ECM-remodeling actions of GHK-Cu, the NO/VEGF effects of BPC-157, and the cytoskeletal effects of TB-500. In the temporal sequence model, KPV is positioned in Phase 1 (0–2 hours) as the first-acting component. At 10 mg per 80 mg vial (12.5% w/w), KPV has the same mass as BPC-157 and TB-500 but is the most abundant component by molar count (~29 μmol) due to its small size (342 Da). For the full blend overview, see the [KLOW peptide blend primer](https://rplpeptides.com/what-is-klow-peptide-blend/)
.

**Q8: How stable is KPV compared to the other KLOW peptides?**

KPV is the most chemically stable peptide in the KLOW blend. It remains >95% intact after 30 days at 4°C in PBS (pH 7.2–7.4). It lacks oxidizable amino acid residues (no methionine, no free cysteine) and is too short for Asp isomerization or significant deamidation. The only relevant chemical event is Pro² cis-trans isomerization, which is catalyzed by cyclophilin enzymes in biological media but occurs negligibly in simple buffer solutions. Long-term storage at −20°C as a lyophilized powder preserves KPV integrity for 12–24 months. For comprehensive stability data and storage recommendations, refer to the [peptide stability guide](https://rplpeptides.com/peptide-stability-preservation-guide/)
 and [storage refrigeration protocol](https://rplpeptides.com/peptide-powder-storage-refrigeration-guide/)
. These stability characteristics make KPV a reliable and predictable component of the KLOW blend from a formulation standpoint.

---

## 10. Entity Glossary

For cross-referencing across chemical and biological databases, search engines, and AI knowledge graph extraction:

| Entity | CAS | PubChem CID | UniProt | ChEBI |  |
| --- | --- | --- | --- | --- | --- |
| KPV | 64883-54-9 | 123870 | — | — | KPV |
| α-MSH | 581-05-5 | 16132366 | P01189 | — | α- |
| POMC (Pro-opiomelanocortin) | — | — | P01189 | — |  |
| MC1R (Melanocortin receptor 1) | — | — | Q01726 | CHEBI:149608 | 1 |
| MC3R (Melanocortin receptor 3) | — | — | P41968 | — | 3 |
| MC4R (Melanocortin receptor 4) | — | — | P32245 | — | 4 |
| MC5R (Melanocortin receptor 5) | — | — | P33032 | — | 5 |
| NF-κB p65 (RELA) | — | — | Q04206 | — | κB p65 |
| IκBα (NFKBIA) | — | — | P25963 | — | IκBα |
| PC1/3 (PCSK1) | — | — | P29120 | — | 1/3 |
| PC2 (PCSK2) | — | — | P16519 | — | 2 |

---

## 11. Further Reading on RPL Peptides

For researchers sourcing KPV and related peptides, the following resources provide detailed technical specifications, quality control documentation, and synthesis methodology:

1. **[KPV Peptide Supplier — China](https://rplpeptides.com/kpv-peptide-supplier-china/)** — Product specifications, ≥98% HPLC purity thresholds, COA documentation, SPPS manufacturing workflow, and bulk supply options for the KPV tripeptide (CAS 64883-54-9).
2. **[What Is the KLOW Peptide Blend?](https://rplpeptides.com/what-is-klow-peptide-blend/)** — The definitive pillar article covering all four KLOW peptides (GHK-Cu, BPC-157, TB-500, KPV), their complementary mechanisms, the temporal sequence model, and blend-level research considerations.
3. **[Peptide Quality Control](https://rplpeptides.com/peptide-quality-control/)** — Analytical verification methodology including RP-HPLC purity assessment, LC-MS identity confirmation, amino acid analysis, residual solvent testing, and orthogonal purity verification standards for research peptides.
4. **[Peptide Stability & Preservation Guide](https://rplpeptides.com/peptide-stability-preservation-guide/)** — Comprehensive stability data covering lyophilized powder shelf life, solution stability at various temperatures and pH ranges, degradation pathway analysis, and preservation best practices.
5. **[Custom Peptide Synthesis — OEM Manufacturing](https://rplpeptides.com/custom-peptide-synthesis-oem-manufacturing-quality-standards-for-bulk-procurement/)** — Technical overview of solid-phase peptide synthesis (SPPS) methodology, scale-up capabilities, quality standards for bulk procurement, and custom sequence manufacturing workflows.

---

## 12. Related Research Guides

The following companion deep-dive articles examine the other peptides in the KLOW blend and adjacent research areas:

- **[Cluster 1: GHK-Cu — The Copper Peptide](../cluster-1-ghk-cu.md)** — Comprehensive analysis of GHK-Cu’s ECM-remodeling mechanisms, copper chelation chemistry, collagen/elastin gene regulation, and TIMP/MMP balance. Both KPV and GHK-Cu indirectly modulate ECM dynamics, though through entirely distinct pathways (MC1R/cAMP vs. copper-dependent LOX activation).
- **[Cluster 2: BPC-157 — The Gastric Pentadecapeptide](../cluster-2-bpc-157.md)** — Detailed coverage of BPC-157’s NO/VEGF/eNOS signaling axis, endothelial protection mechanisms, and FAK/paxillin-mediated cytoskeletal effects.
- **[Cluster 3: TB-500 — The Actin-Modulating Fragment](../cluster-3-tb-500.md)** — In-depth examination of TB-500’s G-actin sequestration mechanism, cell migration dynamics, and the actin-polymerization model. See also: TB-500 — like KPV, TB-500 modulates cellular behavior through an indirect mechanism (actin buffering vs. receptor-mediated signaling).
- **[KLOW80 Peptide Blend — China Supplier](https://rplpeptides.com/klow80-peptide-china-supplier/)** — Product information and specifications for the co-lyophilized KLOW four-peptide research blend (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg per 80 mg vial).
- **[What Is a Research Peptide?](https://rplpeptides.com/what-is-research-peptide/)** — Classification framework, regulatory context, and best practices for research peptide procurement and handling in laboratory settings.

---

## 13. References

1. Getting SJ, Christian HC, Flower RJ, Perretti M. “Activation of melanocortin type 3 receptor as a molecular mechanism for ACTH efficacy.” *Arthritis & Rheumatism*. 2002;46(10):2765–2775. PMID: 12384942.
2. Getting SJ, Kaneva M, Bhardwaj RS, et al. “Melanocortin peptides inhibit NF-κB activation and cytokine release in macrophages via the MC3 receptor.” *The Journal of Immunology*. 2003;171(7):3654–3662. PMID: 14521352.
3. Brzoska T, Luger TA, Maaser C, et al. “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry and perspectives.” *Endocrine Reviews*. 2008;29(5):581–602. PMID: 18612137.
4. Cone RD. “Studies on the physiological functions of the melanocortin system.” *Endocrine Reviews*. 2006;27(7):736–749. PMID: 17077189.
5. Catania A, Gatti S, Colombo G, Lipton JM. “Targeting melanocortin receptors as a novel strategy to control inflammation.” *Pharmacological Reviews*. 2004;56(1):1–29. PMID: 15001661.
6. Bicknell AB. “The tissue-specific processing of pro-opiomelanocortin.” *Journal of Neuroendocrinology*. 2008;20(6):692–699. PMID: 18601691.
7. Dores RM, Baron AJ. “Evolution of POMC: origin and functional diversity of melanocortin and endorphin peptides.” *General and Comparative Endocrinology*. 2011;172(2):185–198. PMID: 21277374.
8. Wikberg JES, Muceniece R, Mandrika I, et al. “New aspects on the melanocortins and their receptors.” *Pharmacological Research*. 2000;42(5):393–420. PMID: 11030775.
9. Luger TA, Brzoska T, Scholzen TE, et al. “The role of α-MSH as a modulator of cutaneous inflammation.” *Annals of the New York Academy of Sciences*. 1999;885:401–425. PMID: 10816672.
10. Getting SJ, Perretti M. “MC3-R as a novel target for anti-inflammatory research.” *Drug News & Perspectives*. 2000;13(1):19–27. PMID: 12937613.
11. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. “The cloning of a family of genes that encode the melanocortin receptors.” *Science*. 1992;257(5074):1248–1251. PMID: 1325670.
12. Verrecchia F, Mauviel A. “Transforming growth factor-β signaling through the Smad pathway: role in extracellular matrix gene expression and regulation.” *Journal of Investigative Dermatology*. 2002;118(2):211–215. PMID: 11841535.
13. Ericson MD, Haskell-Luevano C. “A review of the structure-activity relationships of the melanocortin system: 2012–2022.” *ACS Pharmacology & Translational Science*. 2023;6(3):415–437. PMID: 37639302.
14. Wardlaw SL. “Pro-opiomelanocortin processing: four decades of discovery and emerging concepts.” *Endocrine Reviews*. 2024;45(2):230–255. PMID: 38054612.

---

> **Disclaimer:** This article is intended exclusively for informational and research-context purposes. It does not constitute medical advice, product endorsement, or usage recommendation. KPV is a research chemical that has not been evaluated by the FDA or any equivalent regulatory body for safety or efficacy. All statements regarding biochemical mechanisms are based on published peer-reviewed literature on individual peptide components and should be interpreted as research-context information, not as claims about any specific product’s effects. KPV is not approved as a drug, biologic, dietary supplement, or cosmetic ingredient. Researchers should consult appropriate institutional and regulatory guidelines before acquiring or using any research compound.

---

*For context on KPV’s role within the four-peptide KLOW research blend (GHK-Cu + BPC-157 + TB-500 + KPV), see the* [KLOW Peptide Blend Scientific Primer](https://rplpeptides.com/what-is-klow-peptide-blend/)
.

## Similar Posts

- [https://rplpeptides.com/peptide-powder-storage-refrigeration-guide/](https://rplpeptides.com/peptide-powder-storage-refrigeration-guide/) Peptide Powder Storage: Do Lyophilized Peptides Need Refrigeration? | RPL Peptides TL;DR Key Statistics Metric Value Source Shelf life at -20°C (sealed vial) 2–5 years for most peptides Bachem Technical Note, 2024 Degradation rate ratio: 25°C vs -20°C 50–200× faster at room temperature Manufacturer stability data compilation, 2020–2024 Residual moisture in properly lyophilized cake <1%…
- [https://rplpeptides.com/ghk-cu-copper-tripeptide/](https://rplpeptides.com/ghk-cu-copper-tripeptide/) GHK-Cu (Copper Tripeptide): A Comprehensive Biochemical Deep-Dive — Structure, Gene Regulation, and Copper-Dependent Mechanisms TL;DR — Key Takeaways Table of Contents 1. Molecular Identity GHK-Cu is the coordination complex formed between glycyl-L-histidyl-L-lysine (GHK) and a single Cu²⁺ ion, held in a square-planar ligand field by four nitrogen donor atoms. For researchers sourcing this peptide, GHK-Cu…
- [https://rplpeptides.com/growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-in-laboratory-research-2/](https://rplpeptides.com/growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-in-laboratory-research-2/) CJC-1295 vs Ipamorelin vs Tesamorelin: Mechanism, Half-Life, Evidence & FDA Status (2026) Direct answer: CJC-1295, Ipamorelin, and Tesamorelin are three different growth-hormone secretagogues with different molecular identities, receptors, pharmacokinetics, and regulatory status. CJC-1295 and Tesamorelin are GHRH-receptor agonists, whereas Ipamorelin is a selective GHS-R1a agonist. Tesamorelin is the only FDA-approved drug among the three. CJC-1295…
- [https://rplpeptides.com/tb-500-deep-dive/](https://rplpeptides.com/tb-500-deep-dive/) TB-500 Deep Dive: Actin Sequestration, Cell Migration, and the Thymosin Beta-4 Fragment A comprehensive biochemical examination of the most studied actin-sequestering peptide fragment Key Takeaways (TL;DR) Table of Contents 1. Molecular Identity 1.1 What Is TB-500? TB-500 is the commercial designation for a synthetic peptide fragment derived from thymosin beta-4 (Tβ4) — a 43-amino-acid, 4,963.51…
- [https://rplpeptides.com/how-to-reconstitute-peptides-protocol/](https://rplpeptides.com/how-to-reconstitute-peptides-protocol/) How to Reconstitute Peptides: Step-by-Step Protocol for Research-Grade Solutions | RPL Peptides TL;DR Key Statistics Metric Value Source Peptides soluble in BAC water alone ~80% of standard research peptides RPL Peptides technical support data, 2023–2025 Reconstitution time (gentle swirling) 30–60 seconds for most lyophilized cakes RPL QC laboratory observations Septum coring risk with reused needle…
- [https://rplpeptides.com/peptide-stability-preservation-guide/](https://rplpeptides.com/peptide-stability-preservation-guide/) Peptide Stability & Preservation Guide: From Lyophilized Powder to Reconstituted Solution | RPL Peptides TL;DR Key Statistics Metric Value Source Lyophilized shelf life at -20°C 2–5 years for most peptide sequences Bachem Technical Note, 2024 Lyophilized shelf life at 4°C 6–12 months (sequence-dependent) Thermo Fisher Peptide Storage Guide, 2023 Reconstituted stability at 4°C (BAC water)…

### Leave a Reply [Cancel reply](/kpv-peptide-%CE%B1-msh-11-13/#respond)